Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 6, No. 3, 2011
Issue release date: June 2011
Section title: Review Article · Übersichtsarbeit
Free Access
Breast Care 2011;6:193–198
(DOI:10.1159/000329471)

Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer

Stickeler E.
Universitätsfrauenklinik Freiburg, Germany
email Corresponding Author

Prof. Dr. med. Elmar Stickeler, Universitätsfrauenklinik Freiburg, Hugstetterstr. 55, 79106 Freiburg i.Br., Germany, Tel. +49 761 27031-480, Fax -690, elmar.stickeler@uniklinik-freiburg.de

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Breast cancer clinically represents a heterogeneous disease. Over the last decades, the integration of prognostic and predictive markers in treatment decisions has led to a more individualized and optimized therapy. While prognosis describes the risk of disease recurrence and diseaserelated death after diagnosis without the influence of therapy, prediction illustrates the probability of efficacy or response of a specific therapeutic measure. The substantial decline in breast cancer mortality seen over the last 20 years is primarily due to the delivery of adjuvant systemic therapy. It is important that clinical decisions are made to minimize overtreatment, undertreatment, and incorrect treatment. Improved understanding of breast cancer biology together with the utilization of classical biomarkers and the identification of new markers or profiles is increasingly defining who should receive cancer therapy and what therapy offers the best efficacy. The molecular targets as the prerequisite for successful concepts of specific therapies like antiestrogens, antibodies, or small molecules, have therefore high clinical value in regards to prognosis as well as prediction.

© 2011 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Review Article · Übersichtsarbeit

Published online: June 14, 2011
Issue release date: June 2011

ISSN: 1661-3791 (Print)
eISSN: 1661-3805 (Online)

For additional information: http://www.karger.com/BRC


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.